Key GI and Lung Studies From The European Multidisciplinary Cancer Congress, Stockholm
Key GI and Lung Studies From The European Multidisciplinary Cancer Congress, Stockholm
Jean-Yves Douillard, MD
20110911
2011 Oct 11
Key GI and Lung Studies From The European Multidisciplinary Cancer Congress, Stockholm
2011 Oct 11, Jean-Yves Douillard, MD
Abstract
Several interesting studies were presented. The most interesting for me—even though I am familiar with the data because they were presented at the World Congress on Gastrointestinal Cancer in Barcelona in June—was the VELOUR trial, a study comparing in second-line FOLFIRI (irinotecan/5-FU) in combination with aflibercept (VEGF-trap) to FOLFIRI with placebo.1 This study demonstrated an OS benefit of an 18% reduction of the risk of death, which is highly significant.Progression-free survival (PFS)...
Meet Our Experts
Meet our Advisory and Editorial Boards comprised of physician editors and world-renowned experts.
